Alnylam Pharmaceuticals has been in a crucial position in the biotech market recently. The firm reported a $3B revenue prediction for 2025, boosted by a 151% TTR franchise surge. The company also suffered a downgrade from Wall Street Zen to 'Hold'. The firm has also entered a new cardiovascular partnership with Tenaya, which is seen to potentially change the investment case for Alnylam. Numerous asset management groups have been adjusting their holdings in the company, with some increasing and others reducing their positions. Canaccord Genuity still maintains a buy rating on the firm, while its short interest in February decreased by 12.8%. There has been mixed investor sentiment as per the firm's valuation, with recent share price trends meeting bullish fair value models. Significant investments were also channeled into Alnylam’s manufacturing facility. The firm projected a 2026 revenue around $5.3 billion as it refocuses on a new five-year strategy, and it has been suggested to be potentially trading below fair value.
Alnylam Pharmaceuticals News Analytics from Thu, 18 Sep 2025 07:00:00 GMT to Sat, 21 Mar 2026 21:16:33 GMT -
Rating 0
- Innovation 4
- Information 6
- Rumor 0
